Cero Therapeutics Files 8-K with Corporate Updates
Ticker: CEROW · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1870404
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: CERO
TL;DR
CERO filed an 8-K on 9/25, reporting corporate changes and financial docs. Watch for updates.
AI Summary
Cero Therapeutics Holdings, Inc. filed an 8-K on September 25, 2024, reporting changes to its articles of incorporation or bylaws, other events, and financial statements/exhibits. The company, formerly known as Phoenix Biotech Acquisition Corp., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates potential changes in Cero Therapeutics' corporate structure or operational status, which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant negative news.
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- September 25, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Phoenix Biotech Acquisition Corp. (company) — Former company name
FAQ
What specific amendments were made to the articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text.
What are the 'other events' reported in this 8-K filing?
The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.
When was Cero Therapeutics Holdings, Inc. formerly known as Phoenix Biotech Acquisition Corp.?
The date of the name change from Phoenix Biotech Acquisition Corp. to Cero Therapeutics Holdings, Inc. was June 30, 2021.
What is the Standard Industrial Classification (SIC) code for Cero Therapeutics Holdings, Inc.?
The SIC code for Cero Therapeutics Holdings, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the business address of Cero Therapeutics Holdings, Inc.?
The business address is 201 Haskins Way, Suite 230, South San Francisco, CA 94080.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-10-01 18:46:02
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Marke
- $1.25 million — ggregate cash proceeds of approximately $1.25 million. On September 26, 2024, the Company com
Filing Documents
- ea021621601-8k_cero.htm (8-K) — 42KB
- ea021621601ex3-1_cerothera.htm (EX-3.1) — 293KB
- 0001213900-24-084200.txt ( ) — 628KB
- cero-20240925.xsd (EX-101.SCH) — 4KB
- cero-20240925_def.xml (EX-101.DEF) — 26KB
- cero-20240925_lab.xml (EX-101.LAB) — 36KB
- cero-20240925_pre.xml (EX-101.PRE) — 25KB
- ea021621601-8k_cero_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit Number Description 3.1 Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 1, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Interim Chief Executive Officer 2